ライフサイエンスコーパス: gonorrhoea

1 cal group B vaccines affect the incidence of gonorrhoea.

2 e a vaccine has shown any protection against gonorrhoea.

3 losporins raises the prospect of untreatable gonorrhoea.

4 ausing bacterial meningitis, septicaemia and gonorrhoea.

5 agent of the sexually transmitted infection, gonorrhoea.

6 ible target for novel antimicrobials against gonorrhoea.

7 st herpes simplex virus type 2, syphilis, or gonorrhoea.

8 ve agent of the sexually transmitted disease gonorrhoea.

9 3 cases, accounted for 50% of local cases of gonorrhoea.

10 es and clinical specimens from patients with gonorrhoea.

11 nd controls for analyses: 1241 incidences of gonorrhoea, 12 487 incidences of chlamydia, and 1002 inc

12 imate vaccine effectiveness of MeNZB against gonorrhoea after adjustment for ethnicity, deprivation,

13 physicians in both groups, treated baseline gonorrhoea and chlamydia infections, and assessed 9-mont

14 d chlamydia infections, and assessed 9-month gonorrhoea and chlamydia reinfection as the primary outc

15 lly transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a sugg

16 diseases including meningitis, septicaemia, gonorrhoea and endocarditis, and extracts haem from haem

17 PS biosynthetic enzymes, LgtB from Neisseria gonorrhoea and LgtE from Neisseria meningitidis, and Lps

18 ithin the genus Neisseria cause the diseases gonorrhoea and meningitis.

19 ntly required to address increasing rates of gonorrhoea and the emergence and global spread of antibi

20 nces of trichomoniasis, bacterial vaginosis, gonorrhoea, and chlamydia infection were significantly l

21 he gonococcus, Gc) is the causative agent of gonorrhoea, and has evolved several systems for varying

22 commend that TOC be performed for anogenital gonorrhoea at least 7 or 14 days after administering the

23 We included 77 patients; 5 self-cleared gonorrhoea before treatment and 10 were lost to follow-u

24 prospective vaccine development not only for gonorrhoea but also for meningococcal vaccines.

25 eisseria gonorrhoeae, the causative agent of gonorrhoea, can acquire iron by direct interaction with

26 c could be used again to treat a minority of gonorrhoea cases without raising resistance levels.

27 supported by the absence of oscillations in gonorrhoea cases, where a protective immune response is

28 o MeNZB was associated with reduced rates of gonorrhoea diagnosis, the first time a vaccine has shown

29 s recommended as a single-dose treatment for gonorrhoea from 2005 to 2010, during which time resistan

30 pecific pathogens Neisseria meningitidis, N. gonorrhoea, Haemophilus influenzae and Moraxella catarrh

31 -STI testing and results service (chlamydia, gonorrhoea, HIV, and syphilis) on STI testing uptake and

32 s, rectal chlamydia in 14.6% (5.4-23.8), and gonorrhoea in 13.5% (3.2-23.8).

33 Guidance for treatment of gonorrhoea in England and Wales was changed in 2010 to p

34 icle meningococcal B vaccine (MeNZB) against gonorrhoea in young adults aged 15-30 years in New Zeala

35 Gonorrhoea is a common infectious disease, poorly contro

36 Gonorrhoea is a major global public health problem that

37 Effective treatment of gonorrhoea is fundamental to public health control; howe

38 Gonorrhoea is one of the most common bacterial sexually

39 Gonorrhoea (<0.1% prevalence in women and men) and HIV (

40 -up had significantly lower odds of combined gonorrhoea or chlamydia reinfection than did control pat

41 ligible to receive MeNZB, and diagnosed with gonorrhoea or chlamydia, or both.

42 Women with symptomless gonorrhoea or chlamydial infection having an IUD inserte

43 (the gonococcus Gc), the causative agent of gonorrhoea, promotes attachment of the gonococcus to the

44 been recommended in the UK for treatment of gonorrhoea since 2005.

45 ly transmitted infections (STIs): chlamydia, gonorrhoea, syphilis, and trichomoniasis.

46 m period, and 340 million people acquire new gonorrhoea, syphilis, chlamydia, or trichomonas infectio

47 y recently acquired STIs included chlamydia, gonorrhoea, T. vaginalis and syphilis with rapid plasma

48 cross geographical boundaries to investigate gonorrhoea transmission and to track antimicrobial resis

49 ul tool for epidemiological investigation of gonorrhoea transmission than earlier methods.

50 x virus type 2 (HSV-2), syphilis, chlamydia, gonorrhoea, Trichomonas vaginalis (together defined as '

51 We included patients with anogenital gonorrhoea visiting the Sexually Transmitted Infection C

52 Gonorrhoea was associated with the greatest concentratio